Growth Metrics

Ionis Pharmaceuticals (IONS) Income from Non-Controlling Interests (2017 - 2020)

Ionis Pharmaceuticals (IONS) has disclosed Income from Non-Controlling Interests for 5 consecutive years, with -$1.2 million as the latest value for Q4 2020.

  • For Q4 2020, Income from Non-Controlling Interests fell 105.91% year-over-year to -$1.2 million; the TTM value through Sep 2021 reached -$1.2 million, up 92.19%, while the annual FY2020 figure was -$35.5 million, 489.21% down from the prior year.
  • Income from Non-Controlling Interests hit -$1.2 million in Q4 2020 for Ionis Pharmaceuticals, up from -$12.1 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $19.5 million in Q4 2019 and bottomed at -$17.3 million in Q4 2018.
  • Average Income from Non-Controlling Interests over 4 years is -$6.9 million, with a median of -$9.3 million recorded in 2018.
  • Year-over-year, Income from Non-Controlling Interests skyrocketed 212.67% in 2019 and then tumbled 259.2% in 2020.
  • Ionis Pharmaceuticals' Income from Non-Controlling Interests stood at -$6.2 million in 2017, then tumbled by 177.64% to -$17.3 million in 2018, then surged by 212.67% to $19.5 million in 2019, then crashed by 105.91% to -$1.2 million in 2020.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods came in at -$1.2 million, -$12.1 million, and -$11.9 million for Q4 2020, Q3 2020, and Q2 2020 respectively.